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Introduction
If you knew that you were going to have one of both of your legs amputated due to a
preventable medical condition in the future, then any sane person would want to find a way of
preventing such a disabling and life changing event. Currently peripheral artery disease (PAD) is
a growing threat to health in modern times, which can lead to the situation mentioned above. Due
to diet and lifestyle risk factors, PAD incidence has increased as the world has become more
developed.1 Mankind is unlikely to stop its march onward towards ever more developed states of
living, which likely will mean even less healthy diets and more sedentary lifestyles in the years
to come. With the trends as they are, with more than eight million Americans currently suffering
from PAD and that number actively rising worldwide it is clear that something must be done.2
While it is not currently agreed upon that PAD screening should be conducted in asymptomatic
individuals, this is primarily due to the infeasibility of accurately conducting such screens. A
secondary hurdle is that screening is something that is typically only conducted when there is an
established methodology for preventing the progression of, or reversing the damage done by, the
condition. With things as they are, it might seem that there is no hope for PAD screening, but a
new age is dawning thanks to cutting-edge research.

The Pathophysiology of PAD
PAD is primarily caused by the progression and proliferation of atherosclerotic plaques
formed by the collection of lipids in the intimal layer of arteries. The areas that are at greatest
risk for this are places where the arteries are subjected to lots of stress and movement, and in
places where they branch or curve and turbulent flow is created. Within these regions, the
endothelial cells lining the arteries align differently. This hypothetically allows for damage to the
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endothelial lining to be more likely in these sites than in other locations. Current atherosclerotic
theory states that when an injury occurs to the endothelial cells, a complex cascade of expression
and release of chemoattractants and adhesion proteins is started. These proteins then play a role
in capturing and tethering platelets, lymphocytes, and monocytes that then accumulate at the
damaged region. These lymphocytes and monocytes then migrate to the intimal layer of the
vessel. Low density lipoproteins (LDL) then follow this migration and become oxidized. The
monocytes differentiate to become macrophages and begin releasing proinflammatory substances
and cytokines. The macrophages then phagocytize the LDL and become foam cells that
proliferate along with smooth muscle, causing a thickening of the intimal layer. A fibrous cap
then develops over the lesion leading to progressive stenosis, occlusion, and sometime
thrombosis. The sequelae of this pathogenic process are claudication, ischemia, and even
infarction of the affected tissue or limb.

Current PAD Screening
Currently screening is most commonly performed via ankle brachial index (ABI). ABI is
a quick and cost-effective test that can be performed in the primary care setting.3 Cost is a major
determining factor in many aspects of health care and the methodology of PAD screening is no
exception. While magnetic resonance angiography (MRA) is the undisputed gold standard for
diagnosing the presence and severity of PAD, its cost is prohibitive. The national average is
currently approximately $7,000 for imaging of the lower extremities.4 While angiography with
its many varied forms is agreed upon as the gold standard for confirming a diagnosis of PAD, its
cost makes its use prohibitive except for in determining the extent of disease severity and
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viability of revascularization. It is clear why ABI is the preferred screening method when you
learn that it costs only a little more than $300 on average.5

ABI is a test that is performed by taking the systolic blood pressure in each of a patient’s
brachial arteries then taking the systolic blood pressure in both of the patient’s dorsalis pedis and
posterior tibial arteries. You then divide the higher of the two systolic values for each lower
extremity by the highest systolic value obtained from the upper extremities. ABIs for each lower
extremity can be calculated in this way. A normal ABI falls in the range of 1.0-1.4. Values above
1.4 are indicative of a noncompressible calcified vessel, values under 0.9 are diagnostic of PAD.
In one study when an MRA showing 50% stenosis in pelvic or lower limb arteries was used as a
reference standard for diagnosable PAD, ABI was found to have a sensitivity of 15% to 20% and
a specificity of 99%.6 Other studies have demonstrated the same high levels of specificity, yet
have shown extremely variable levels of sensitivity ranging from 15% to 79%. A concerning fact
is that the two groups with the lowest ABI sensitivity were found to be diabetics and the
elderly.7, 8

The Case Against ABI
There are further arguments against the use of ABI in addition to its relatively
cumbersome and time-consuming nature. One such reason is that the test itself has an 80%-85%
chance of giving a false positive result.9 This is one of the reasons that many are shying away
from PAD screening because without greater reliability and ease of testing the risk of causing
untoward physical and psychological harm is too great. Further reason comes from the fact that
due to unknown physiologic factors there is variability in ABI results for different races.10
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Unfortunately, ABI is also often performed and interpreted improperly.5 A reality in modern
healthcare is that time is the enemy of the clinician and sometimes of proper patient care as well.
One study cited a lack of time as being the deciding factor for purposely performing ABIs
incorrectly.11 This admission speaks volumes when you consider that the average ABI when
properly preformed takes on average only five minutes.12

If taking an extra five minutes is enough for clinicians to deem a test too cumbersome to
be properly performed then regardless of the test’s innate value to patient care, it is essentially
worthless. It would seem that there must be a better way. The good news is that, thanks to
cellular adhesion proteins, the answer may be as simple as adding a few more items to the
patient’s lab orders.

The Role of Cellular Adhesion Proteins
Endothelial dysfunction has been noted as playing a key role in the development of
atherosclerotic disease.13 Many plasma markers of endothelial function have been identified and
are actively being studied for their potential role in PAD screening. One promising feature of
these plasma markers is that some have been shown to be significantly associated with PAD in
high risk populations such as African Americans and Hemodialysis patients.14, 15 One of these
markers, thrombomodulin (TM) is an endothelial glycoprotein that has a role in the protein C
anticoagulant pathway. Interestingly, the plasma concentration of TM reflects the level of
endothelial damage, which is logical when one learns that TM has been identified as a marker of
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microvascular endothelial damage.16, 17, 18 Unsurprisingly, this was able to be substantiated in a
2016 study conducted by Tokyo Medical and Dental University.19

Another marker being studied is P-selectin, which is involved in the bonding of
endothelial cells and the activation, rolling, and attachment of leukocytes.20 In a comprehensive
study involving over 2,000 participants P-selectin was found to be significantly associated with
the development of PAD. Not only that, it was also significantly associated with both prevalent
and incidental PAD, in addition to progression from normal ABI to an ABI less than 0.9.1 Taking
these correlations one step further P-selectin also has been found to accelerate atherosclerotic
plaque progression.21 Could perhaps the future of PAD screening lie in the measurement of
serum concentrations of one or more of these cell adhesion proteins?

How Cellular Adhesion Proteins Change the Game
While it may be difficult with the current amount of research data to definitively prove
that either ABI or cellular adhesion plasma markers are a superior modality for PAD screening in
terms of sensitivity and specificity, what certainly can be determined is that any easy and cost
effective test like ABI that is not utilized, is inferior to a modality that can offer comparable
results and is more likely to be used regularly. As the popular sports aphorism goes, “You miss
100% of the shots that you don’t take.” This can easily be applied to the screening of patients. If
a test is deemed to be time consuming then it won’t be used in the primary care setting.

It is a well agreed upon fact that longer patient visits yield better results for patient
outcomes as they allow for more elements of care to be considered and integrated into the
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treatment plan.22 Clinicians and their clinical teams have an innate sense of this and work within
the constraints of the modern day healthcare system to bring as much benefit as possible to the
patient. What this means is trimming the fat and eliminating any part of the visit that is seen by a
team member as being unnecessary. The consultation with the provider cannot be cut and is
prioritized over all other parts of the visit. One thing that is often cut from the visits of the
patients most in need of PAD screening is ABI testing.12 In order to ensure that patients are
screened for PAD, one potential answer is to have the screening performed when the patient isn’t
at their primary care provider’s office.

There are few options for when this encounter could happen then without creating
another separate visit. One place that must be visited in the course of the normal patient care is
the lab. This required stop offers an excellent place for screening tests to be incorporated. A
blood draw takes only seconds longer to perform if it is for five tubes of blood to be drawn
versus two. By taking advantage of this fact the actual testing involved in screening for PAD can
be moved out of the general practitioner’s office. All a provider need do in that case would be to
add an order for the cell adhesion proteins that are associated with PAD to the lab slip.

The Future of PAD Screening
Another benefit of adopting this screening method is that the cost per patient for the lab
test comes out to only $12.98.23 Based on information from a Health Service Research study and
the Health Cost Institute it can be extrapolated that the average ABI which takes five minutes on
average to complete in a primary care PA or NP office costs $30.05 based solely on the time it
takes.24, 25 This of course doesn’t factor in the cost of the personnel and equipment required to
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perform the test which is why the actual figure as mentioned is $300 on average. The math
speaks for itself. Measuring soluble P-selectin has been shown by multiple large scale studies to
be an effective method for assessing the presence and progression of PAD and offers a
reasonable alternative to a test modality that no longer seems to offer the most logical solution to
screening patients.1, 14 The current literature offers droves of evidence for the move towards
utilizing soluble plasma markers for such a purpose, though there is of course as in any
burgeoning new field room for further research. The possibilities for the future of these markers
is bright as they have even been identified as targets for future therapeutic agents to reverse or
stop the advance of PAD.
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